Investigational drug · Phase 3
eRapa
Also called: Encapsulated Rapamycin, Encapsulated sirolimus
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Familial Adenomatous Polyposis (FAP), Familial Adenomatous Polyposis.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
5
Any phase or sponsor naming "eRapa"
First trial start
2021
Jan 18, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "eRapa", any sponsor or status.
Conditions studied
As listed on its trial records.
- Familial Adenomatous Polyposis (FAP)
- Familial Adenomatous Polyposis
Largest trials
Live from ClinicalTrials.gov: studies naming "eRapa" as an intervention, largest first.
- Phase 3 Trial of eRapa in Patients With Familial Adenomatous PolyposisPivotal-lookingRecruiting
Rapamycin Holdings Inc.Industry
NCT06950385 · 168 participants (planned) · Start Jul 18, 2025 · Primary completion Jul 2030
Drug: eRapa (encapsulated rapamycin); Placebo · For: Familial Adenomatous Polyposis (FAP)
Sites: Arcadia, California; New Haven, Connecticut; Washington D.C., District of Columbia · 29 sites in all
- Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer PreventionPivotal-lookingActive, not recruiting
Robert SvatekAcademic, hospital or other
NCT04375813 · 166 participants (planned) · Start Jan 25, 2021 · Primary completion Jan 2027
Drug: eRapa; Placebos · For: Non-muscle Invasive Bladder Cancer
Sites: Dallas, Texas; San Antonio, Texas
Rapamycin Holdings Inc.Industry
NCT04230499 · 30 participants · Start Jan 18, 2021 · Primary completion Dec 11, 2024
Drug: Encapsulated Rapamycin (eRapa) · For: Familial Adenomatous Polyposis
Sites: Ann Arbor, Michigan; Cleveland, Ohio; Columbus, Ohio · 4 sites in all
Rapamycin Holdings, Inc. dba Emtora BiosciencesIndustry
NCT03618355 · 15 participants · Start Aug 28, 2018 · Primary completion Dec 2, 2019
Drug: eRapa (encapsulated rapamycin) · For: Prostate Cancer
Sites: San Antonio, Texas
Biodexa PharmaceuticalsIndustry
NCT07689942
Drug: eRapa (encapsulated rapamycin) · For: Familial Adenomatous Polyposis (FAP)
Newest research
PubMed records naming it or its code names, newest first.
- 19F MRI-Traceable PLGA Nanocarriers: Influence of Particle Architecture on Co-Encapsulation and Release of Immiscible Payloads.
Larreina Vicente N, Lodrini A, Groeneveld E, et al. · ACS Biomater Sci Eng 2026
- Phase II Trial of Encapsulated Rapamycin to Reduce Polyp Burden Associated with Familial Adenomatous Polyposis.
Broderick JC, Samadder NJ, Stoffel E, et al. · Clin Cancer Res 2026
- Exosomal delivery of rapamycin modulates blood-brain barrier penetration and VEGF axis in glioblastoma.
Song LL, Tang YP, Qu YQ, et al. · J Control Release 2025
- Rapamycin Reduces Carcinogenesis and Enhances Survival in Mice when Administered after Nonlethal Total-Body Irradiation.
Sowers AL, Gohain S, Edmondson EF, et al. · Radiat Res 2024
- Nanoliposomes Encapsulated Rapamycin/Resveratrol to Induce Apoptosis and Ferroptosis for Enhanced Colorectal Cancer Therapy.
Jia M, Tan X, Yuan Z, et al. · J Pharm Sci 2024
- Modulation of immunosuppressive effect of rapamycin via microfluidic encapsulation within PEG-PLGA nanoparticles.
Wu W, Liu R, Guo J, et al. · J Biomater Appl 2024
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.